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ABSTRACT
Objective: We investigated a large sample of patients with amyotrophic lateral sclerosis (ALS) at
rest in order to assess the value of 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) PET as a biomarker
to discriminate patients from controls.
Methods: A total of 195 patients with ALS and 40 controls underwent brain 18F-FDG-PET, most
within 5 months of diagnosis. Spinal and bulbar subgroups of ALS were also investigated.
Twenty-five bilateral cortical and subcortical volumes of interest and cerebellum were taken into
account, and 18F-FDG uptakes were individually normalized by whole-brain values. Group analy-
ses investigated the ALS-related metabolic changes. Discriminant analysis investigating sensi-
tivity and specificity was performed using the 51 volumes of interest as well as age and sex.
Metabolic connectivity was explored by voxel-wise interregional correlation analysis.
Results: Hypometabolismwas found in frontal, motor, and occipital cortex and hypermetabolism in
midbrain, temporal pole, and hippocampus in patients with ALS compared to controls. A similar
metabolic pattern was also found in the 2 subgroups. Discriminant analysis showed a sensitivity
of 95% and a specificity of 83% in separating patients from controls. Connectivity analysis
found a highly significant positive correlation between midbrain and white matter in corticospinal
tracts in patients with ALS.
Conclusions: 18F-FDG distribution changes in ALS showed a clear pattern of hypometabolism in
frontal and occipital cortex and hypermetabolism in midbrain. The latter might be interpreted as
the neurobiological correlate of diffuse subcortical gliosis. Discriminant analysis resulted in high
sensitivity and specificity in differentiating patients with ALS from controls. Once validated by
diseased-control studies, the present methodology might represent a potentially useful biomarker
for ALS diagnosis.
Classificaton of evidence: This study provides Class III evidence that 18F-FDG-PET accurately
distinguishes patients with ALS from normal controls (sensitivity 95.4%, specificity 82.5%).
Neurology® 2014;83:1067–1074
GLOSSARY
18F-FDG 5 18F-2-fluoro-2-deoxy-D-glucose; ALS 5 amyotrophic lateral sclerosis; BA 5 Brodmann area; CI 5 confidence
interval; DA 5 discriminant analysis; FDRcorr 5 corrected for multiple comparisons with the false discovery rate option;
ROC 5 receiver operating characteristic.
Amyotrophic lateral sclerosis (ALS) diagnosis is based on clinical history, neurologic examina-
tion, and symptoms progression and is supported by neurophysiologic examination.1 The role
of neuroimaging in ALS is currently limited to the exclusion of other disease processes whose
symptoms might explain the clinical and electrophysiologic signs. Despite a large number of
studies, only a few biochemical, neurophysiologic, and brain structural investigations have been
performed to explore the discriminative value of ALS biomarkers.2 Recently an MRI study
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differentiated patients from controls with an
accuracy of 90%,3 although it is often difficult
to perform MRI analyses in patients with
severe motor and respiratory impairments.
18F-2-fluoro-2-deoxy-D-glucose PET (18F-
FDG-PET) measures glucose consumption in
the astrocyte-synapse functional unit.4 It might
show reduced glucose utilization in neurode-
generation as well as increased glucose utiliza-
tion during inflammatory processes.5
Besides the reduced 18F-FDG uptake seen
in motor areas,6 the few studies of 18F-FDG-
PET performed in patients with ALS have re-
ported frontal lobe,7 diffuse cortical and basal
ganglia,8 and parietal and occipital cortex9
hypometabolism. Midbrain hypermetabolism
was also recently described by our group.10
Although these findings support the hypothe-
sis that ALS may be regarded as a multisystem
disorder, no study assessed the value of func-
tional imaging in ALS diagnosis.
The aim of the present investigation was
3-fold: (1) to replicate the metabolic changes pre-
viously described in a far larger group of patients
with ALS; (2) to assess the possible discriminant
diagnostic value of 18F-FDG-PET on a volume
of interest–based discriminant analysis; and (3)
to identify the brain functional connectivity
underlying ALS.
METHODS Participants. A total of 195 patients with ALS
(mean age 63.2 years [SD 11.6, range 21–86]; females 78/195)
who agreed to undergo 18F-FDG-PET were prospectively recruited
between June 2011 and February 2013 at the Turin ALS center. All
cases had probable laboratory-supported, probable, or definite ALS
according to El Escorial ALS revised criteria.1 Most patients
underwent 18F-FDG-PET within 5 months of diagnosis. Median
time between diagnosis and PET examination was 4.1 months
(interquartile range 5 37–44).
The patients were further classified according to the clinical pre-
sentation at the time of PET scan, i.e., spinal (n 5 136, mean age
62.5 years [SD 12.6, range 21–86]; females 45/136) and bulbar (n5
59, mean age 64.7 years [SD 10.3, range 42–86]; females 32/59). For
this study, we considered bulbar patients to be those with bulbar onset
and a loss of less than 4 points on the spinal section of the revised ALS
Functional Rating Scale (items 4–12). Fifteen patients (9 with spinal
and 6with bulbar subtype) carried aGGGGCChexanucleotide repeat
expansion in the first intron of the C9ORF72 gene ($30 repeats). No
statistically significant age difference was found between the 2 sub-
groups; sex differed at x2 5 7.70, p , 0.01.
Forty participants (mean age 62 years [SD 14.4, range 27–84];
females 11/40) who were referred to the PET center for a suspected
diagnosis of lung cancer in whom no oncologic disease was dis-
closed with 18F-FDG-PET/CT and who had a normal neurologic
assessment served as controls. Exclusion criteria were presence of
major systemic illness, major vision disturbances, psychiatric ill-
nesses, and diseases affecting brain functioning and metabolism.10
Image acquisition and analysis. Detailed methods were pre-
viously described.10,11 PET/CT scans were acquired by a Discov-
ery ST-E System (General Electric) and images were acquired
through 2 sequential scans: CT scan of the brain (thickness of
3.75 mm, 140 kV, 60–80 mA/s) and PET brain scan (1 field of
view of 30 transaxial cm). PET scan was initiated immediately
after the CT examination in order to use CT data for the
attenuation correction of the PET data. Data were collected in
1283 128 matrices with a reconstructed voxel of 2.343 2.343
2.00 mm.
We carried out preprocessing and statistical analyses by
SPM8-normalizing the images to a customized template obtained
using FDG-PET and 3D MRI scans of 40 age-matched healthy
controls performed at the same center.12 Briefly, each FDG-
PET scan was first coregistered to the pertinent MRI scan
(6 parameters, rigid body transformation) using the coregistration
algorithm available in the SPM8 package. Each MRI was then
spatially normalized to the SPM8 T1-MRI template using an
affine plus nonlinear transformation, and the resulting deforma-
tion field was applied to the coregistered FDG-PET scan. The
spatially normalized PET images were then averaged to obtain a
mean PET image, which was finally smoothed with an 8-mm
isotropic Gaussian filter.13
We performed group comparisons between controls, patients
with ALS, and spinal and bulbar subgroups at a threshold of p ,
0.05 corrected for multiple comparisons with the false discovery
rate option (FDRcorr). If significant clusters were found, the more
conservative threshold at p , 0.05 corrected for multiple com-
parisons with the familywise error option was also tested. We
identified the Brodmann areas (BAs) matching the SPM output
to the Talairach coordinates using the subroutine implemented
by Matthew Brett (http://brainmap.org/index.html). Finally, we
explored the sensitivity, specificity, and accuracy values to distin-
guish ALS from controls, segmenting 65 BAs in all 235 partic-
ipants. In order to reduce the number of variables and hence
increase the statistical strength of the study, we merged regions
with similar anatomo-functional characteristics (i.e., BAs 11 and
47, orbitofrontal cortex; BAs 24 and 32, anterior cingulate cortex;
BAs 44, 45, and 46, dorsolateral prefrontal cortex; BAs 1, 2, 3,
and 4, somatomotor cortex; BAs 23 and 31, posterior cingulate
cortex, amygdala and hippocampus, medial temporal lobe, cor-
tex), resulting in 51 volumes of interest (25 bilaterally and cere-
bellum). Since we expected that strong asymmetries could
characterize pathologic conditions, homologous regions in the
opposite hemispheres were considered separately. Discriminant
analysis was performed by SPSS (version 19) and generalized
linear model analysis. Cross-validation was performed in both
analyses. This analysis aims to discriminate patients from con-
trols, providing a Class III level of evidence.
Voxel-wise interregional correlation analysis. The cluster
found to be hypermetabolic in patients with ALS compared to con-
trols was saved as a volume of interest. The mean of 18F-FDG
uptake values within this volume of interest was computed in the
spatially normalized scans of each of the 235 participants and
divided by whole-brain counts. These values were covaried with
the 18F-FDG uptake values to find regions showing significant
voxel-wise correlations at p , 0.05 FDRcorr. This provided
parametric maps of metabolic connectivity across participants.13
Standard protocol approvals, registrations, and patient
consents. The study design was approved by the institutional ethics
committee. Patients and controls signed written informed consent.
RESULTS Study population.No relevant differences in
age and sex were found between patients and controls.
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ALS diagnosis was confirmed in all patients at
1-year follow-up.
Group comparison. Controls vs ALS. Patients with ALS
showed 3 large clusters of relative hypometabolism
compared to controls at p , 0.05 FDRcorr (figure
1A, table 1). The clusters included bilateral primary
and associative visual cortex and bilateral and premo-
tor cortex, as well as left sensorimotor, frontal eyes
field and dorsolateral prefrontal cortex. Large regions
with significantly increased metabolism in patients
with ALS compared to controls were found in mid-
brain, bilateral superior temporal gyrus, and hippo-
campi, bilaterally (figure 1B; table 1).
Controls vs spinal patients. We found a very similar
pattern at p, 0.05 FDRcorr when spinal patients were
compared to controls, with hypometabolic clusters in
spinal patients in bilateral primary and associative
visual cortex and in bilateral prefrontal and premotor
cortex. Spinal patients showed a relative hypermetab-
olism in bilateral midbrain, superior temporal gyrus,
and right cerebellum (figure 2, A and B; table e-1 on
the Neurology® Web site at Neurology.org).
Controls vs bulbar patients. Compared to controls,
bulbar patients were relatively hypometabolic at
p , 0.05 FDRcorr in bilateral clusters including
motor, premotor, and prefrontal cortex. Only mid-
brain was relatively hypermetabolic in bulbar patients
compared to controls (figure 2, C and D; table e-2).
Bulbar patients vs spinal patients. Compared to spinal
patients, bulbar patients showed a relative hypometa-
bolic cluster in left motor and premotor cortex at a
statistical threshold of puncorrected ,0.001 at voxel
level. The opposite comparison did not show any
significant result.
Voxel-wise interregional correlation analysis. In patients
with ALS, the midbrain hypermetabolic cluster re-
gressed against 18F-FDG relative uptake in the whole
brain significantly correlated at p , 0.05 FDRcorr
(besides the expected autocorrelation in midbrain)
with metabolism in cerebellar cortex (cerebellar ton-
sil, tuber, and pyramid of the vermis and most of the
cerebellar lobules) and with the white matter tracts,
following the motor fibers of the corona radiata to
reach primary motor cortex (figure 3). In controls this
correlation was limited to 2 small cerebellar clusters
bilaterally.
Discriminant analysis. Following cross-validation,
discriminant analysis (DA) resulted in an accuracy of
87.7% (95% confidence interval [CI]: 82.8–91.6) in
separating patients and controls, with a sensitivity of
88.7% (CI: 83.4–92.7) and a specificity of 82.5 (CI:
67.2–92.7). The area under the receiver operating
characteristic (ROC) curve was 92.9% (CI: 89.7–
96.2). The best discrimination was obtained by the
generalized linear model analysis using the following
volumes of interest: right premotor, left superior
Figure 1 Metabolic differences in controls vs patients with ALS
Figure displays regions of significant metabolic differences: (A) hypometabolic regions in amyotrophic lateral sclerosis
(ALS); (B) hypermetabolic regions in ALS. Images are color-graded in terms of z values. Talairach coordinates and further
details are provided in table 1.
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parietal, bilateral prefrontal, left orbitofrontal, left
insular, right primary and associative visual, left
temporal, right anterior cingulate, left fusiform, and
bilateral parietal cortices, as well as cerebellum, right
thalamus, bilateral putamen, and medial temporal
lobe, with an accuracy of 93.2% (CI: 89.2–96.5), a
sensitivity of 95.4% (CI: 91.4–97.9), and a specificity
of 82.5% (CI: 67.2–92.7) (figure 4). The area under
the ROC curve was 94.5% (CI: 91.7–97.3) and the
difference with DA applied to all 51 volumes of
interest was not statistically significant.
DISCUSSION We found highly significant hypome-
tabolism in frontal, premotor, and occipital cortex in
195 patients with ALS compared to controls. The
same hypometabolic pattern characterized the spinal
subtype, whereas in bulbar patients the analysis showed
only frontal and prefrontal hypometabolism, more ros-
tral than spinal patients. Premotor cortex was signifi-
cantly hypometabolic in all 3 comparisons. In a
cohort of patients 6 times as large, this study repro-
duced the metabolic changes previously found in pa-
tients with ALS.10 Some of the findings, not
highlighted in the previous study,10 are likely the result
of the larger sample size and the higher statistical reli-
ability of the present investigation, since the sampling
error decreases with the increase of the sample size. The
significantly lower frontal metabolism found in the
patient groups is not surprising since frontal and pre-
frontal cortex hypometabolism represents the neurobi-
ological correlate of the cognitive impairment in
patients with ALS.14,15 The hypometabolism found
in primary and associative visual cortex is consistent
with the extramotor spreading of ALS as described by
several surface-based morphometry16 and diffusion
tensor MRI studies,17,18 showing cortical thinning
and decreased fractional anisotropy in these regions,
respectively.
Moreover, we confirmed the relative midbrain
hypermetabolism in all patient groups and disclosed a
significantly higher relative FDG uptake in superior
temporal gyrus and hippocampi in patients with ALS,
in particular spinal patients. Midbrain hypermetabo-
lism can be considered one of the signatures of ALS
and might be related to both motor neuron degenera-
tion and astrocytosis. Functional investigations found
reduced neuronal density in pyramidal cells and inter-
neurons in motor and premotor cortices,19 widespread
astrocytosis,20 and microglial activation in motor cortex
and pons.21 Along with activated microglia and macro-
phages, a 60% increase in 18F-FDGmetabolic rate con-
stant was found in areas of neuroinflammation.5
During the course of neurodegenerative disorders, dead
neurons and axons are replaced by astrocytes filling the
Table 1 Results of 18F-FDG brain PET comparison between controls and patients with ALS
Cluster extent pFDRcorr Maximum z score Region Talairach coordinates Cortical region BA
CTR-ALS 4,011 0.000a 6.15 Right occipital 8.0 290.0 24.0 Lingual gyrus 17
0.001a 5.78 Right occipital 4.0 279.0 4.0 Lingual gyrus 18
0.002a 5.61 Left occipital 24.0 286.0 22.0 Lingual gyrus 18
0.014 5.00 Left occipital 220.0 292.0 26.0 Inferior occipital gyrus 17
2,604 0.003a 5.46 Right frontal 40.0 8.0 36.0 Precentral gyrus 9
0.004 5.30 Right frontal 38.0 21.0 52.0 Middle frontal gyrus 6
3,479 0.003 5.43 Left frontal 240.0 28.0 24.0 Middle frontal gyrus 46
0.026 4.84 Left frontal 242.0 15.0 29.0 Middle frontal gyrus 9
0.026 4.83 Left parietal 251.0 211.0 50.0 Postcentral gyrus 3
0.026 4.77 Left frontal 250.0 0.0 42.0 Precentral gyrus 6
0.029 4.73 Left frontal 238.0 18.0 49.0 Superior frontal gyrus 8
ALS-CTR 1,174 0.005a 5.38 Left temporal 234.0 21.0 215.0 Temporal pole 38
0.007a 5.21 Left temporal 226.0 216.0 211.0 Parahippocampal gyrus
1,065 0.005a 5.36 Right temporal 38.0 1.0 222.0 Temporal pole 38
0.047 4.66 Right cerebrum 38.0 226.0 29.0 Caudate
0.063 4.51 Right temporal 26.0 216.0 29.0 Parahippocampal gyrus
823 0.007a 5.33 Right cerebrum 8 224 238 Midbrain
0.047 4.76 Left cerebrum 26 222 234 Midbrain
Abbreviations: 18F-FDG 5 18F-2-fluoro-2-deoxy-D-glucose; ALS 5 amyotrophic lateral sclerosis (n 5 195); BA 5 Brodmann area; CTR 5 control (n 5 40);
pFDRcorr 5 p , 0.05 corrected for multiple comparisons with the false discovery rate.
ap , 0.05 corrected for multiple comparisons with the familywise error.
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space left empty by their shrinkage.22 Several studies
reported reactive astrogliosis fanning out from primary
motor cortex to the descending white matter tracts and
the brainstem.20,23–25 This strong glial reaction causes
proliferation of astrocytes, the main determinant of
18F-FDG uptake in the astrocyte-neuron functional
unit.4 Furthermore, PET studies in ALS found microg-
lia proliferation and astrocytosis in subcortical white
matter, pons, and midbrain, suggesting glial cell
involvement in the disease.21,26,27 Astrocytes account
for about 50% of glucose consumption at rest5,28
since glycolytic activity, including anaerobic glycol-
ysis, is higher in glial cells than in neurons, with the
former taking up glucose directly from intraparen-
chymal capillaries. Glutamate-induced glycolysis in
astrocytic syncytium provides lactate as substrate for
neuronal firing,29 and in ALS glutamate excess is
proportional to the presence of dysarthria and dys-
phagia.30 Taken together, these phenomena may
result in regions of neuronal degeneration in an
increased relative 18F-FDG uptake due to the higher
density of astrocytes and microglia in patients with
ALS compared to controls.
Besides the midbrain, our study showed relative
hypermetabolism in the superior temporal gyrus
and hippocampus bilaterally in patients with ALS
compared to controls. A recent study demonstrated
a significant increase of activated glial cells in primary
and supplementary motor and temporal cortex in
ALS.27 The latter region (figure 1B) is immediately
adjacent to the white matter tracts containing axonal
fibers that run in the corona radiata and ultimately
into centrum semiovale connecting cerebral cortex
and midbrain. In our study, the degeneration of axons
in corticofugal fibers is indirectly suggested by the
voxel-wise interregional correlation analysis showing
a parallel increase in metabolism in midbrain and
white matter tracts connecting the latter to motor
cortex in ALS (figure 3). These findings replicate with
functional neuroimaging the recently reported
Figure 2 Metabolic differences in controls vs spinal patients and bulbar patients
Figure displays regions of significant metabolic differences: (A) hypometabolic regions in spinal patients; (B) hypermetabolic regions in spinal patients; (C)
hypometabolic regions in bulbar patients; (D) hypermetabolic regions in bulbar patients. Images are color-graded in terms of z values. Talairach coordinates
and further details are provided in tables e-1 and e-2.
Figure 3 Voxelwise interregional correlation analysis in ALS of midbrain hypermetabolic cluster and 18F-FDG
uptake in whole brain
Figure displays regions of metabolically correlated areas at p, 0.05 FDRcorr. Images are color-graded in terms of z values.
18F-FDG 5 18F-2-fluoro-2-deoxy-D-glucose; ALS 5 amyotrophic lateral sclerosis; FDRcorr 5 p value corrected for multiple
comparisons with the false discovery rate.
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selectively reduced fractional anisotropy in corticospi-
nal tracts.31 On the other hand, the partial volume
effect associated with the relatively low spatial resolu-
tion of PET and the possible temporal atrophy in ALS
might have caused a smearing of the hypermetabolic
signal in white matter bundles into isocenters corre-
sponding to gray matter regions (superior temporal
gyrus and hippocampi), resulting in an artifactual
topographic mismatch.
The second important result of the study is the
capability of a routine analysis of 18F-FDG-PET data
to discriminate patients with ALS from controls with
a sensitivity of 89% and a specificity of 82.5%. This
was further strengthened by the generalized linear
model analysis in which a selected number of regions
showed an even higher sensitivity (95.4%) with the
same specificity (82.5%; figure 4), suggesting a pos-
sible value of 18F-FDG-PET in correctly identifying
patients relative to healthy persons. Furthermore, the
characteristic pattern of hypermetabolism and hypo-
metabolism found in patients with ALS and the high
discrimination accuracy associated with a specific set
of regions involved in this pattern suggest a prospec-
tive value of 18F-FDG-PET in differentiating ALS
from other pathologic conditions.32 In this respect,
studies including diseased controls, in particular
ALS-mimic syndromes, as well as longitudinal studies
assessing the prognostic value of the methodology, are
needed to further test the clinical value of 18F-FDG-
PET in ALS.
This very high sensitivity, equal or superior to that
achieved when investigating severe Alzheimer dis-
ease,33,34 is seldom obtained by functional neuroimaging,
often due to the statistical limitations associated with
having a small number of participants. This restric-
tion is usually overcome by multicenter studies in
which large patient cohorts are recruited but in
which images originating from different cameras
have to be normalized and interpolated. In the pre-
sent study, the largest ALS 18F-FDG-PET investiga-
tion performed so far, the size of the patient and
control samples allowed for high accuracy to be reli-
ably obtained. Also, we applied the strict statistical
constraint of leave-one-out cross-validation. In fact,
cross-validation evaluates the discriminant capability
of the statistical model, assessing how the results
could be generalized to independent data. Without
cross-validation, the overfitting (the adaptation to
characteristics peculiar to the sample) could induce
overestimation of model accuracy and misclassifica-
tion of independent samples. Leave-one-out tech-
nique classifies each participant by a model fitted to
all remaining participants, creating a virtually inde-
pendent validation set with the same number of ob-
servations as the original sample. Cross-validation
prevents the predictive model from being forced by
data and is of paramount importance in neuroimag-
ing, in which comparison groups are difficult and
costly to recruit. Similar discrimination values in
ALS were recently obtained by more invasive CSF
analyses, although in smaller patient cohorts.2,35 Fur-
thermore, the accuracy of the present study is supe-
rior to the accuracy of the state-of-the-art and time-
consuming MRI analyses, often not feasible in the
presence of major motor, respiratory, and psycholog-
ical disability.3 For this reason, many of the recruited
patients could not be investigated by MRI, prevent-
ing a valuable comparison of functional and structural
findings. On the other hand, the relatively simple
analysis protocol, taking a few minutes and based
on freeware along with routine 18F-FDG-PET scan,
might render this methodology easily accessible to
most nuclear medicine departments.
We did not perform a systematic independent
interregional correlation analysis covarying 18F-FDG-
PET uptake by the values of hypometabolic clusters.
Severe anatomical damage of primary motor cortex,
corpus callosum, and corticospinal tract degeneration
results in extramotor neuronal loss or thinning in
frontotemporal and parietal regions, as described
by surface-based morphometry and diffusion tensor
MRI studies,36–38 and is associated with regional hypo-
metabolism. In this respect, investigating the networks
Figure 4 Discrimination between controls and patients with amyotrophic lateral
sclerosis obtained by generalized linear model
Generalized linear model discriminant model: receiver operating characteristic (ROC) curve.
Discriminant capabilities were evaluated by cross-validation using Brodmann areas (BAs):
BA6: premotor cortex; BA7: precuneus; BA9 and 10: prefrontal cortex; BA 11 and 47: orbi-
tofrontal cortex; BA13: insula; BA17: primary visual cortex; BA18: visual association cortex;
BA21: middle temporal gyrus; BA22: superior temporal gyrus; BA24 and 32: anterior cingu-
late cortex; BA37: fusiform gyrus; BA39: inferior parietal cortex; BA40: temporoparietal
junction; medial temporal lobe: amygdala and hippocampus. Area under ROC curve 94.5%.
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underlying the metabolic deficits would not have
added relevant information to the current knowledge
about the spreading of hypometabolism associated
with neuronal damage in ALS.
We acknowledge that the use of a control group
with a PET scan negative for oncologic disease is a
suboptimal solution with respect to a group of
healthy volunteers. However, the control group was
specifically set up for this study, strict exclusion crite-
ria were applied, and the same injection/acquisition/
reconstruction protocols and scanner were used for
both patients and controls. This is of utmost impor-
tance in neuroimaging studies, in which the number
of potential confounding variables has to be reduced
as much as possible. On the other hand, including a
control group of neurologically normal participants
undergoing PET scan for other reasons prevents
healthy individuals from being exposed to radiation.
The need for reliable biomarkers for ALS has been
advocated and various potential candidates have been
identified.39 The possible contribution of the widely
available 18F-FDG-PET technique in identifying disease
progression and suggesting the most appropriate diag-
nostic algorithm lies in establishing definite metabolic
patterns for ALS subgroups (i.e., bulbar and spinal var-
iants). Studies comparing patients with ALS to patients
with ALS-mimic syndromes, such as cervical myelopa-
thy, and motor neuron disease variants, such as primary
lateral sclerosis and Kennedy disease, are needed to bet-
ter define the sensitivity and specificity of 18FDG-PET
in the diagnosis of ALS. Longitudinal studies will also be
needed to investigate not only the neuroradiologic
course of the disease (as compared to the natural one)
but also the predictive value of 18F-FDG-PET in dis-
closing the regional involvement before the dissemina-
tion of symptoms. The effect of therapeutic agents could
also be evaluated at a presymptomatic stage in familial
forms, helping to select the more appropriate therapy.
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